The role of carcinogen-metabolizing enzyme polymorphisms in cancer susceptibility

Reproductive Toxicology

Volumn 11, Issue 2-3, 1997, Pages 397-412

  Gonzalez, Frank J ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; CARCINOGEN; CYTOCHROME P450; DRUG METABOLIZING ENZYME; GLUTATHIONE TRANSFERASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); XENOBIOTIC AGENT;

BLADDER CANCER; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; COLON CANCER; CONFERENCE PAPER; DISEASE PREDISPOSITION; ENZYME POLYMORPHISM; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; HUMAN; LIVER CANCER; LUNG CANCER; METABOLISM; NEOPLASM; NONHUMAN; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING; XENOBIOTIC METABOLISM;

EID: 0031105286     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0890-6238(96)00154-2     Document Type: Conference Paper

References (211)

1. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet. 1993;9:138-41.
2. Yuspa SH, Dlugosz AA, Cheng CK, Denning MF, Tennenbaum T, Glick AB, Weinberg WC. Role of oncogenes and tumor suppressor genes in multistage carcinogenesis. J Invest Dermatol. 1994;103:90S-5S.
3. Hennings H, Click AB, Greenhalgh DA, Morgan DL, Strickland JE, Tennenbaum T, Yuspa SH. Critical aspects of initiation, promotion, and progression in multistage epidermal carcinogenesis. Proc Soc Exp Biol Med. 1993;202:1-8.
4. Jackson MA, Stack HF, Waters MD. The genetic toxicology of putative nongenotoxic carcinogens. Mutat Res. 1993;296:241-77.
5. Barrett JC. Mechanisms for species differences in receptormediated carcinogenesis. Mutat Res. 1995;333:189-202.
6. Costa M. Model for the epigenetic mechanism of action of nongenotoxic carcinogens. Am J Clin Nutr. 1995;61:666S-9S.
7. Harris CC. The 1995 Walter Hubert Lecture - molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene. Br J Cancer. 1996;73:261-269.
8. Gonzalez FJ. Genetic polymorphism and cancer susceptibility: fourteenth Sapporo Cancer Seminar. Cancer Res. 1995;55:710-5.
9. Kalow W. Pharmacogenetics: its biologic roots and the medical challenge. Clin Pharmacol Ther. 1993;54:235-41.
10. Daly AK, Cholerton S, Armstrong M, Idle JR. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. Environ Health Perspect. 1994;102(Suppl 9): 55-61.
11. Guengerich FP. Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res. 1988;48: 2946-54.
12. Guengerich FP. Cytochromes P-450. Comp Biochem Physiol C. 1988;80:1-4.
13. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. P450 suoerfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996;6:1-42.
14. Gonzalez FJ, Aoyama T, Gelboin HV. Activation of promutagens by human cDNA-expressed cytochrome P450s. Prog Clin Biol Res. 1990;340B:77-86.
15. Aoyama T, Yamano S, Guzelian PS, Gelboin HV, Gonzalez FJ. Five of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate aflatoxin Bl. Proc Natl Acad Sci USA. 1990;87:4790-3.
16. Eaton DL, Gallagher EP, Bammler TK, Kunze KL. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics. 1995;5:259-74.
17. Guengerich FP, Kim DH, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol. 1991;4:168-79.
18. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270:414-23.
19. Kimura S, Gonzalez FJ, Neben DW. Tissue-specific expression of the mouse dioxin-inducible P( 1)450 and P(3)450 genes: differential transcriptional activation and mRNA stability in liver and extrahepatic tissues. Mol Cell Biol. 1986;6:1471-7.
20. Savas U, Jefcoate CR. Dual regulation of cytochrome P450EF expression via the aryl hydrocarbon receptor and protein stabilization in C3H/10T1/2 cells. Mol Pharmacol. 1994;45:1153-9.
21. vas U, Bhattacharyya KK, Christou M, Alexander DL, Jefcoate CR. Mouse cytochrome P-450EF, representative of a new 1B subfamily of cytochrome P-450s. Cloning, sequence determination, and tissue expression. J Biol Chem. 1994;269:14905-11.
22. Swanson HI, Bradfield CA. The AH-receptor: genetics, structure and function. Pharmacogenetics. 1993;3:213-30.
23. Fujii-Kuriyama Y, Ema M, Mimura J, Sogawa K. Ah receptor: a novel ligand-activated transcription factor. Exp Clin Immunogenet. 1994; 11:65-74.
24. Ema M, Suzuki M, Morita M, Hirose K, Sogawa K, Matsuda Y, Gotoh O, Saijoh Y, Fujii H, Hamada H, Fujii-Kuriyama Y. cDNA cloning of a murine homologue of Drosophila singleminded, its mRNA expression in mouse development, and chromosome localization. Biochem Biophys Res Commun. 1996;218: 588-94.
25. 2 tension. Proc Natl Acad Sci USA. 1995;92:5510-14.
26. Reyes H, Reisz-Porszasz S, Hankinson O. Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science. 1992;256: 1193-5.
27. Denison MS, Whitlock JP Jr. Xenobiotic-inducible transcription of cytochrome P450 genes. J Biol Chem. 1995;270:18175-8.
28. Puga A, Nebert DW. Evolution of the P450 gene superfamily and regulation of the murine Cyp1a1 gene. Biochem Soc Trans. 1990; 18:7-10.
29. Nebert DW, Jones JE. Regulation of the mammalian cytochrome PI-450 (CYP1A1) gene. Int J Biochem. 1989;21:243-52.
30. Fujii-Kuriyama Y, Ema M, Mimura J, Matsushita N, Sogawa K. Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene. Pharmacogenetics. 1995;5:S149-53.
31. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977;2: 584-6.
32. Idle JR, Smith RL. Polymorphisms of oxidation at carbon centers of drugs and their clinical significance. Drug Metab Rev. 1979; 9:301-17.
33. Eichelbaum M. Polymorphic oxidation of debrisoquine and sparteine. Prog Clin Biol Res. 1986;214:157-67.
34. Gonzalez FJ. The CYP2D subfamily In: Cytochromes P450: metabolic and toxicologie aspects. C. loannides, Ed., Boca Raton, FL: CRC Press; 1996. pp. 183-210.
35. Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FG, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen V, Wolf CR, Zanger U. Nomenclature for human CYP2D6 alleles. Pharmacogenetics. 1996;6:193-201.
36. Caporaso N, DeBaun MR, Rothman N. Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association. Pharmacogenetics. 1995;5: S129-34.
37. Gonzalez FJ, Idle JR. Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin Pharmacokinet. 1994;26:59-70.
38. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46:594-8.
39. Goldstein JA, De Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 1994;4: 285-99.
40. Femandez-Salguero P, Gonzalez FJ. The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics. 1995;5:S123-8.
41. Fernandez-Salguero P, Hoffman SM, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, Pelkonen O, Huang JD, Evans WE, Idle JR. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet. 1995;57:651-60.
42. Cholerton S, Idle ME, Vas A, Gonzalez FJ, Idle JR. Comparison of a novel thin-layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine. J Chromatogr. 1992;575: 325-30.
43. Rautio A, Kraul H, Kojo A, Salmela E, Pelkonen O. Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics. 1992;2:227-33.
44. Kawajiri K, Watanabe J, Eguchi H, Hayashi S. Genetic polymorphisms of drug-metabolizing enzymes and lung cancer susceptibility. Pharmacogenetics. 1995;5:S70-3.
45. McBride OW, Umeno M, Gelboin HV, Gonzalez FJ. A Taq I polymorphism in the human P450IIE1 gene on chromosome 10 (CYP2E). Nucleic Acids Res. 1987;15:10071.
46. Uematsu F, Kikuchi H, Ohmachi T, Sagaini I, Motomiya M, Kamataki T, Komori M, Watanabe M. Two common RFLPs of the human CYP2E gene. Nucleic Acids Res. 1991;19:2803.
47. Uematsu F, Kikuchi H, Motomiya M, Abe T, Sagami I, Ohmachi T, Wakui A, Kanamaru R, Watanabe M. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn J Cancer Res. 1991;82:254-6.
48. Uematsu F, Kikuchi H, Abe T, Motomiya M, Ohmachi T, Sagami I, Watanabe M. MspI polymorphism of the human CYP2E gene. Nucleic Acids Res. 1991;19:5797.
49. Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem (Tokyo). 1991; 110:559-65.
50. Watanabe J, Hayashi S, Kawajiri K. Different regulation and expression of the human CYP2E1 gene due to the Rsal polymorphism in the 5′-flanking region. J Biochem (Tokyo). 1994; 116: 321-6.
51. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1 [published erratum appears in Chem Res Toxicol. 1991 May-Jun;4(3):389], Chem Res Toxicol. 1990;3:566-573.
52. Carriere V, Goasduff T, Ratanasavanh D, Morel F, Gautier JC, Guillouzo A, Beaune P, Berthou F. Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chem Res Toxicol. 1993;6:852-7.
53. Carrire V, Berthou F, Baird S, Belloc C, Beaune P, de Waziers I. Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics. 1996;6:203-211.
54. Kirn RB, O'Shea D, Wilkinson GR. Relationship in healthy subjects between CYP2E1 genetic polymorphisms and the 6-hydroxylation of chlorzoxazone: a putative measure of CYP2E1 activity. Pharmacogenetics. 1994;4:162-5.
55. O'Shea D, Davis SN, Kirn RB, Wilkinson GR. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther. 1994; 56:359-67.
56. Kim RB, O'Shea D. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther. 1995;57: 645-55.
57. Vesell ES, Seaton TD, A-Rahim YI. Studies on interindividual variations of CYP2E1 using chlorzoxazone as an in vivo probe. Pharmacogenetics. 1995;5:53-7.
58. Grant DM. Molecular genetics of the N-acetyltransferases. Pharmacogenetics. 1993;3:45-50.
59. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM, Hein DW, Lin HJ, Meyer U A, Relling MV. Nomenclature for N-acetyltransferases. Pharmacogenetics. 1995;5:1-17.
60. Weber WW. Acetylation. Birth Defects. 1990;26:43-65.
61. Weber WW, Vatsis KP. Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood. Pharmacogenetics. 1993;3:209-12.
62. Cribb AE, Nakamura H, Grant DM, Miller MA, Spielberg SP. Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism. Biochem Pharmacol. 1993;45:1277-82.
63. Kadlubar FF, Butler MA, Kaderlik KR, Chou HC, Lang NP. Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ Health Perspect. 1992; 98:69-74.
64. Coles B, Ketterer B. The role of glutathione and glutathione transferases in chemical carcinogenesis. Crit Rev Biochem Mol Biol. 1990;25:47-70.
65. Mannervik B, Awasthi YC, Board PG, Hayes JD, Di Ilio C, Ketterer B, Listowsky l, Morgenstern R, Muramatsu M, Pearson WR. Nomenclature for human glutathione transferases [letter]. Biochem J. 1992;282:305-6.
66. Ketterer B, Harris JM, Talaska G, Meyer DJ, Pemble SE, Taylor JB, Lang NP, Kadlubar FF. The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. Environ Health Perspect. 1992;98:87-94.
67. Seidegard J, DePierre JW, Pero RW. Hereditary interindividual differences in the glutathione transferase activity towards transstilbene oxide in resting human mononuclear leukocytes are due to a particular isozyme(s). Carcinogenesis. 1985;6:1211-6.
68. Seidegard J, Pero RW. The hereditary transmission of high glutathione transferase activity towards trans-stilbene oxide in human mononuclear leukocytes. Hum Genet. 1985;69:66-8.
69. Seidegard J, Vorachek WR, Pero RW, Pearson WR. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA. 1988;85:7293-7.
70. Joseph P, Xie T, Xu Y, Jaiswal AK. NAD(P)H:quinone oxidoreductasel (DT-diaphorase): expression, regulation, and role in cancer. Oncol Res. 1994;6:525-32.
71. Traver RD, Horikoshi T, Danenberg KD, Stadibauer TH, Danenberg PV, Ross D, Gibson NW. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res. 1992;52:797-802.
72. Eickelmann P, Schulz WA, Rohde D, Schmitz-Drager B, Sies H. Loss of heterozygosity at the NAD(P)H: quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line. Biol Chem Hoppe Seyler. 1994;375:439-5.
73. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics. 1995;5:199-206.
74. Michejda CJ, Kroeger Koepke MB. Carcinogen activation by sulfate conjugate formation. Adv Pharmacol. 1994;27:331-63.
75. Matsui M, Homma H. Biochemistry and molecular biology of drug-metabolizing sulfotransferase. Int J Biochem. 1994;26: 1237-47.
76. Jin CJ, Miners JO, Burchell B, MacKenzie PI. The glucuronidation of hydroxylated metabolites of benzo[a]pyrene and 2-acetylaminofluorene by cDNA-expressed human UDP-glucuronosyl-transferases. Carcinogenesis. 1993;14:2637-9.
77. MacKenzie PI, Rodbourn L, Iyanagi T. Glucuronidation of carcinogen metabolites by complementary DNA-expressed uridine 5′-diphosphate glucuronosyltransferases. Cancer Res. 1993;53: 1529-33.
78. Babu SR, Lakshmi VM, Owens IS, Zenser TV, Davis BB. Human liver glucuronidation of benzidine. Carcinogenesis. 1994; 15: 2003-7.
79. Owens IS, Ritter JK. Gene structure at the human UGT1 locus creates diversity in isozyme structure, substrate specificity, and regulation. Prog Nucleic Acid Res Mol Biol. 1995;51:305-38.
80. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants [published erratum appears in Hum Mol Genet. 1994 Jul;3(7):1214]. Hum Mol Genet. 1994;3:421-8.
81. Hassett C. Robinson KB, Beck NB, Omiecinski CJ. The human microsomal epoxide hydrolase gene (EPHX1): complete nucleotide sequence and structural characterization. Genomics. 1994;23: 433-2.
82. Hines RN, Cashman JR, Philpot RM, Williams DE, Ziegler DM. The mammalian flavin-containing monooxygenases: molecular characterization and regulation of expression. Toxicol Appl Pharmacol. 1994;125:1-6.
83. Phillips IR, Dolphin CT, Clair P, Hadley MR, Hutt AJ, McCombie RR, Smith RL, Shephard EA. The molecular biology of the flavin-containing monooxygenases of man. Chem Biol Interact. 1995;96:17-32.
84. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993;3:73-6.
85. Furlong CE, Costa LG, Hassett C, Richter RJ, Sundstrom JA, Adler DA, Disteche CM, Omiecinski CJ, Chapline C, Crabb JW. Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. Chem Biol Interact. 1993;87:35-48.
86. Li FP. Translational research on hereditary colon, breast, and ovarian cancers. J Natl Cancer Inst Monogr. 1995;17:1-4.
87. Clavel J, Hemon D. Fundamentals of case-control studies. Pharmacogenetics. 1993;3:160-5.
88. London SJ, Daly AK, Thomas DC, Caporaso NE, Idle JR. Methodological issues in the interpretation of studies of the CYP2D6 genotype in relation to lung cancer risk [letter; comment]. Pharmacogenetics. 1994;4:107-8.
89. Kellermann G, Shaw CR, Luyten-Kellerman M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N Engl J Med. 1973;289:934-7.
90. Paigen B, Ward E, Reilly A, Houten L, Gurtoo HL, Minowada J, Steenland K, Havens MB, Sartori P. Seasonal variation of aryl hydrocarbon hydroxylase activity in human lymphocytes. Cancer Res. 1981 ;41:2757-61.
91. Gurtoo HL, Parker NB, Paigen B, Havens MB, Minowada J, Freedman HJ. Induction, inhibition, and some enzymological properties of aryl hydrocarbon hydroxylase in fresh mitogen-activated human lymphocytes. Cancer Res. 1979;39:4620-9.
92. Gurtoo HL, Minowada J, Paigen B, Parker NB, Hayner NT. Factors influencing the measurement and the reproducibility of aryl hydrocarbon hydroxylase activity in culutred human lymphocytes. J Natl Cancer Inst. 1977;59:787-8.
93. Paigen B, Minowada J, Gurtoo HL, Paigen K, Parker NB, Ward E, Hayner NT, Bross ID, Bock F, Vincent R. Distribution of aryl hydrocarbon hydroxylase inducibility in cultured human lymphocytes. Cancer Res. 1977;37:1829-37.
94. Kouri RE, McKinney CE, Slomiany DJ, Snodgrass DR, Wray NP, McLemore TL. Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res. 1982;42: 5030-7.
95. Ward E, Paigen B, Steenland K, Vincent R, Minowada J, Gurtoo HL, Sartori P, Havens MB. Aryl hydrocarbon hydroxylase in persons with lung or laryngeal cancer. Int J Cancer. 1978;22:384-9.
96. Korsgaard R, Trell E. Aryl hydrocarbon hydroxylase and bronchogenic carcinomas associated with smoking [letter]. Lancet. 1978;1:1103-4.
97. Trell E, Korsgaard R, Kitzing P, Lunggren K, Mattiasson I. Aryl hydrocarbon hydroxylase inducibility and carcinoma of oral cavity [letter]. Lancet. 1978;1:109.
98. Trell E, Oldbring J, Korsgaard R, Mattiasson I. Aryl hydrocarbon hydroxylase inducibility and carcinoma of renal pelvis and ureter [letter]. Lancet. 1977;2:612.
99. Trell E, Korsgaard R, Hood B, Kitzing P, Norden G. Simonsson BG. Letter: Aryl hydrocarbon hydroxylase inducibility and laryngeal carcinomas. Lancet. 1976;2:140.
100. Paigen B, Ward E, Steenland K, Havens M, Sartori P. Aryl hydrocarbon hydroxylase inducibility is not altered in bladder cancer patients or their progeny. Int J Cancer. 1979;23:312-5.
101. Neben DW, Petersen DD, Puga A. Human AH locus polymorphism and cancer: inducibility of CYP1A1 and other genes by combustion products and dioxin. Pharmacogenetics. 1991;1:68-78.
102. Ema M, Matsushita N, Sogawa K, Ariyama T, Inazawa J, Nemoto T, Ota M, Oshimura M, Fujii-Kuriyama Y. Human arylhydrocarbon receptor: functional expression and chromosomal assignment to 7p21. J Biochem (Tokyo). 1994;116:845-51.
103. Ema M, Ohe N, Suzuki M, Mimura J, Sogawa K, Ikawa S, Fujii-Kuriyama Y. Dioxin binding activities of polymorphic forms of mouse and human arylhydrocarbon receptors. J Biol Chem. 1994;269:27337-43.
104. Poland A, Bradfield C. A brief review of the Ah locus. Tohoku J Exp Med. 1992;168:83-7.
105. Poland A, Palen D, Glover E. Analysis of the four alleles of the murine aryl hydrocarbon receptor. Mol Pharmacol. 1994;46:915-21.
106. Hayashi S, Watanabe J, Nakachi K, Eguchi H, Gotoh O, Kawajiri K. Interindividual difference in expression of human Ah receptor and related P450 genes. Carcinogenesis. 1994;15:801-6.
107. McLemore TL, Adelberg S, Liu MC. McMahon NA, Yu SJ. Hubbard WC, Czerwinski M, Wood TG, Storeng R, Lubet RA. Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst. 1990;82:1333-9.
108. Petersen DD, McKinney CE, Ikeya K, Smith HH, Bale AE, McBride OW, Nebert DW. Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet. 1991;48:720-5.
109. Hayashi S, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem (Tokyo). 1991; 110:407-11.
110. Crofts F, Taioli E, Trachman J, Cosma GN, Currie D, Toniolo P, Garte SJ. Functional significance of different human CYP1A1 genotypes. Carcinogenesis. 1994;15:2961-3.
111. Cosma G, Crofts F, Taioli E, Toniolo P, Garte S. Relationship between genotype and function of the human CYP1A1 gene. J Toxicol Environ Health. 1993;40:309-16.
112. Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A. Anttila S, Vainio H. Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev. 1992;l:485-9.
113. Drakoulis N, Cascorbi I, Brockmoller J, Gross CR, Roots I. Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region. Clin Investig. 1994;72:240-8.
114. Kihara M, Noda K. Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphisms in a Japanese population. Carcinogenesis. 1995;16:2331-6.
115. Nakachi K, Imai K, Hayashi S, Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res. 1993;53:2994-9.
116. Hayashi S, Watanabe J, Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and Mu-class glutathione S-transferase genes. Jpn J Cancer Res. 1992;83:866-70.
117. Nakachi K, Imai K, Hayashi S, Watanabe J, Kawajiri K. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res. 1991;51:5177-80.
118. Kawajiri K, Fujii-Kuriyama Y. P450 and human cancer. Jpn J Cancer Res. 1991;82:1325-35.
119. Hayashi S, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem (Tokyo). 1991;110:407-11.
120. Nakachi K, Hayashi S, Kawajiri K, Imai K. Association of cigarette smoking and CYP1Al polymorphisms with adenocarcinoma of the lung by grades of differentiation. Carcinogenesis. 1995;16: 2209-13.
121. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett. 1990;263:131-3.
122. Kawajiri K, Nakachi K, Imai K, Hayashi S, Watanabe J. Individual differences in lung cancer susceptibility in relation to polymorphisms of P-450IA1 gene and cigarette dose. Princess Takamatsu Symp. 1990;21:55-61.
123. Shields PG, Sugimura H, Caporaso NE, Petruzzelli SF, Bowman ED, Trump BF, Weston A, Harris CC. Polycyclic aromatic hy drocarbon-DNA adducts and the CYP1A1 restriction fragment length polymorphism. Environ Health Perspect. 1992;98:191-4.
124. Shields PG, Bowman ED, Harrington AM, Doan VT, Weston A. Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes. Cancer Res. 1993;53:3486-92.
125. London SJ, Daly AK, Fairbrother KS, Holmes C, Carpenter CL, Navidi WC, Idle JR. Lung cancer risk in African-Americans in relation to a race-specific CYP1A1 polymorphism. Cancer Res. 1995;55:6035-7.
126. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Sorsa M, Vainio H. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer. Pharmacogenetics. 1992;2:259-63.
127. Tefre T, Ryberg D, Haugen A, Nebert DW, Skaug V, Brogger A, Borresen AL. Human CYP1A1 (cytochrome P(1)450) gene: lack of association between the MspI restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics. 1991;1:20-5.
128. Wedlund PJ, Kimura S, Gonzalez FJ, Nebert DW. 1462V mutation in the human CYP1A1 gene: lack of correlation with either the MspI 1.9 kb (M2) allele or CYP1A1 inducibility in a threegeneration family of east Mediterranean descent. Pharmacogenetics. 1994;4:21-6.
129. Seidegard J, Pero RW, Miller DG, Beattie EJ. A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. Carcinogenesis. 1986;7:751-3.
130. Nazar-Stewart V, Motulsky AG, Eaton DL, White E, Hornung SK, Leng ZT, Stapleton P, Weiss NS. The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma. Cancer Res. 1993;53:2313-8.
131. Brockmoller J, Kerb R, Drakoulis N, Nitz M, Roots I. Genotype and phenotype of glutathione S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls. Cancer Res. 1993;53:1004-11.
132. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Vainio H. The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis. 1993;14:1479-81.
133. Alexandrie AK, Sundberg MI, Seidegard J, Tornling G, Rannug A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis. 1994;15:1785-90.
134. Kihara M, Noda K. Distribution of GSTM1 null genotype in relation to gender, age and smoking status in Japanese lung cancer patients. Pharmacogenetics. 1995;5:574-9.
135. London SJ, Daly AK, Cooper J, Navidi WC, Carpenter CL, Idle JR. Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles County, California. J Natl Cancer Inst. 1995;87:1246-53.
136. Kato S, Bowman ED, Harrington AM, Blomeke B, Shields PG. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo [see comments]. J Natl Cancer Inst. 1995; 87:902-7.
137. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. The CYP1Al gene and cancer susceptibility. Crit Rev Oncol Hematol. 1993;14:77-87.
138. 462: Assessment of a role for the rare allele in Carcinogenesis. Cancer Res. 1996;56:3926-3933.
139. Landi MT, Bertazzi PA, Shields PG, Clark G, Lucier GW, Garte SJ, Cosma G, Caporaso NE. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics. 1994;4:242-6.
140. Cosma G, Crofts F, Currie D, Wirgin I, Toniolo P, Garte SJ. Racial differences in restriction fragment length polymorphisms and messenger RNA inducibility of the human CYP1A1 gene. Cancer Epidemiol Biomarkers Prev. 1993;2:53-7.
141. Anttila S, Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, Nurminen T, Vainio H. Combined effect of CYP1A1 inducibility and GSTM1 polymorphism on histological type of lung cancer. Carcinogenesis. 1994;15:1133-5.
142. Vaury C, Laine R, Noguiez P, de Coppet P, Jaulin C, Praz F, Pompon D, Amor-Gueret M. Human glutathione S-transferase Ml null genotype is associated with a high inducibility of cytochrome P450 1A1 gene transcription. Cancer Res. 1995;55: 5520-3.
143. Anttila S, Hirvonen A, Vainio H, Husgafvel-Pursiainen K, Hayes JD, Ketterer B. Immunohistochemical localization of glutathione S-transferases in human lung. Cancer Res. 1993;53:5643-8.
144. Anttila S, Luostarinen L, Hirvonen A, Elovaara E, Karjalainen A, Nurminen T, Hayes JD, Vainio H, Ketterer B. Pulmonary expression of glutathione S-transferase M3 in lung cancer patients: association with GSTM1 polymorphism, smoking, and asbestos exposure. Cancer Res. 1995;55:3305-9.
145. Goto I, Yoneda S, Yamamoto M, Kawajiri K. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutothione S-transferase genes in patients with nonsmall cell lung cancer. Cancer Res. 1996;56:3725-3730.
146. Pearson WR, Vorachek WR, Xu SJ, Berger R, Hart I, Vannais D, Patterson D. Identification of class-mu glutathione transferase genes GSTM1-GSTM5 on human chromosome 1p13. Am J Hum Genet. 1993;53:220-33.
147. Crespi CL, Penman BW, Gelboin HV, Gonzalez FJ. A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis. 1991;12:1197-1201.
148. Ayesh R, Idle JR, Ritchie JC, Crothers MJ, Hetzel MR. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature. 1984;312:169-70.
149. Caporaso N, Hayes RB, Dosemeci M, Hoover R, Ayesh R, Hetzel M, Idle J. Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype. Cancer Res. 1989;49:3675-9.
150. Roots I, Drakoulis N, Ploch M, Heinemeyer G, Loddenkemper R, Minks T, Nitz M, Otte F, Koch M. Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk. Klin Wochenschr. 1988;66(Suppl 11):87-97.
151. Benitez J, Ladero JM, Jara C, Carrillo JA, Cobaleda J, Llerena A, Vargas E, Munoz JJ. Polymorphic oxidation of debrisoquine in lung cancer patients. Eur J Cancer. 1991;27:158-61.
152. Duche JC, Joanne C, Barre J, de Cremoux H, Dalphin JC, Depierre A, Brochard P, Tillement JP, Bechtel P. Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer. Br J Clin Pharmacol. 1991;31:533-6.
153. Horsmans Y, Desager JP, Harvengt C. Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility? Biomed Pharmacother. 1991;45:359-62.
154. Wolf CR, Smith CA, Gough AC, Moss JE, Vallis KA, Howard G, Carey FJ, Mills K, McNee W, Carmichael J. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis. 1992;13:1035-8.
155. Stucker I, Cosme J, Laurent P, Cenee S, Beaune P, Bignon J, Depierre A, Milleron B, Hemon D. CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure. Carcinogenesis. 1995;16:2759-64.
156. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Pelkonen O, Vainio H. PCR-based CYP2D6 genotyping for Finnish lung cancer patients. Pharmacogenetics. 1993;3:19-27.
157. Tefre T, Daly AK, Armstrong M, Leathart JB, Idle JR, Brogger A, Borresen AL. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics. 1994;4:47-57.
158. Dolzan V, Rudolf Z, Breskvar K. Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls. Carcinogenesis. 1995;16:2675-8.
159. Bouchardy C, Benhamou S, Dayer P. The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res. 1996; 56:251-3.
160. Cholerton S, Arpanahi A, McCracken N, Boustead C, Taber H, Johnstone E, Leathart J, Daly AK, Idle JR. Poor metabolisers of nicotine and CYP2D6 polymorphism [letter]. Lancet. 1994;343: 62-3.
161. Benowitz NL, Jacob P III, Perez-Stable E. CYP2D6 phenotype and the metabolism of nicotine and cotinine. Pharmacogenetics. 1996;6:239-242.
162. Uematsu F, Kikuchi H, Motomiya M, Abe T, Ishioka C, Kanamaru R, Sagami I, Watanabe M. Human cytochrome P450IIE1 gene: DraI polymorphism and susceptibility to cancer. Tohoku J Exp Med. 1992;168:113-7.
163. Uematsu F, Ikawa S, Kikuchi H, Sagami I, Kanamaru R, Abe T, Satoh K, Motomiya M, Watanabe M. Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: possible relevance to low smoking exposure. Pharmacogenetics. 1994;4:58-63.
164. Song BJ, Matsunaga T, Hardwick JP, Park SS, Veech RL, Yang CS, Gelboin HV, Gonzalez FJ. Stabilization of cytochrome P450j messenger ribonucleic acid in the diabetic rat. Mol Endocrinol. 1987;1:542-7.
165. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol. 1984;17:459-64.
166. Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther. 1991;50:508-19.
167. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther. 1993;53:503-14.
168. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF, Kadlubar FF. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics. 1992;2:116-27.
169. Tang BK, Zhou Y, Kadar D, Kalow W. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics. 1994;4:117-24.
170. Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics. 1994;4:109-16.
171. McQuilkin SH, Nierenberg DW, Bresnick E. Analysis of withinsubject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities. Cancer Epidemiol Biomarkers Prev. 1995;4:139-46.
172. Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev. 1994;3:413-21.
173. Wohlleb JC, Hunter CF, Blass B, Kadlubar FF, Chu DZ, Lang NP. Aromatic amine acetyltransferase as a marker for colorectal cancer: environmental and demographic associations. Int J Cancer. 1990;46:22-30.
174. Lang NP, Butler MA, Massengill J, Lawson M, Stotts RC, Hauer-Jensen M, Kadlubar FF. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prev. 1994;3: 675-82.
175. Vatsis KP, Weber WW. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys. 1993;301:71-6.
176. Bell DA, Stephens EA, Castranio T, Umbach DM, Watson M. Deakin M, Elder J, Hendrickse C, Duncan H, Strange RC. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res. 1995;55: 3537-42.
177. Bell DA, Badawi AF, Lang NP, Ilett KF, Kadlubar FF, Hirvonen A. Polymorphism in the N-acetyltransferase l (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res. 1995; 55:5226-9.
178. Zhong S, Wyllie AH, Barnes D, Wolf CR, Spurr NK. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis. 1993;14: 1821-4.
179. Szarka CE, Pfeiffer GR, Hum ST. Everley LC, Balshem AM, Moore DF, Litwin S, Goosenberg EB, Frucht H, Engstrom PF. Glutathione S-transferase activity and glutathione S-transferase mu expression in subjects with risk for colorectal cancer. Cancer Res. 1995;55:2789-93.
180. Chenevix-Trench G, Young J, Coggan M, Board P. Glutathione S-transferase M1 and T1 polymorphisms: susceptibility to colon cancer and age of onset. Carcinogenesis. 1995;16:1655-7.
181. Ward E, Carpenter A, Markowitz S, Roberts D, Halperin W. Excess number of bladder cancers in workers exposed to orthotoluidine and aniline [see comments]. J Natl Cancer Inst. 1991; 83:501-6.
182. Lower CM Jr, Nilsson T, Nelson CE, Wolf H, Gamsky TE, Bryan GT. N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect. 1979; 29:71-9.
183. Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E, Kahn MA. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet. 1982;2:842-5.
184. Evans DA. Eze LC, Whibley EJ. The association of the slow acetylator phenotype with bladder cancer. J Med Genet. 1983;20: 330-3.
185. Karakaya AE, Cok I, Sardas S, Gogus O, Sardas OS. N-Acetyltransferase phenotype of patients with bladder cancer. Hum Toxicol. 1986;5:333-5.
186. Hayes RB, Bi W, Rothman N, Broly F, Caporaso N, Feng P, You X, Yin S, Woosley RL, Meyer UA. N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis. 1993;14:675-8.
187. Hayes RB. Genetic susceptibility and occupational cancer. Med Lav. 1995;86:206-13.
188. Vineis P, Bartsch H, Caporaso N, Harrington AM, Kadlubar FF, Landi MT, Malaveille C, Shields PG, Skipper P, Talaska G. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature. 1994; 369:154-6.
189. The impact of interindividual variation in NAT2 activity on benzidine urinary metabolites and urothelial DNA adducts in exposed workers. Rothman N, Bhatnagar VK, Hayes RB, Zenser TV, Kashyap SK, Butler MA, Bell DA, Lakshmi V, Jaeger M, Kashyap R, Hirvonen A, Schulte PA, Dosemeci M, Hsu F, Parikh DJ, Davis BB, Talaska G. Proc Natl Acad Sci USA. 1996;93:5084-5089.
190. Zenser TV, Lakshmi VM, Rustan TD, Doll MA, Deitz AC, Davis BB, Hein DW. Human N-acetylation of benzidine: role of NAT1 and NAT2. Cancer Res. 1996;56:3941-3947.
191. d. Brockmoller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferase M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res. 1996;56:3915-3925.
192. e. Lang NP, Kadlubar FF. Aromatic and helerocyclie amine metabolism and phenotyping in humans. Prog Clin Biol Res 1991;372:33-47.
193. Taylor JA, Umbach D, Castranio T, Paulson D, Robertson D, Mohler J, Bell D. Gene-environment interaction between smoking and acetylation in bladder cancer. Proc Am Assoc Cancer Res. 1995;36:1681.
194. Badawi AF, Hirvonen A, Bell DA, Lang NP, Kadlubar FF. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res. 1995;55:5230-7.
195. Lee SW, Jang IJ, Shin SG, Lee KH, Yim DS, Kirn SW, Oh SJ, Lee SH. CYP1A2 activity as a risk factor for bladder cancer. J Korean Med Sci. 1994;9:482-9.
196. Brockmoller J, Kerb R, Drakoulis N, Staffeldt B, Roots I. Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study. Cancer Res. 1994;54:4103-11.
197. Daly AK, Thomas DJ, Cooper J, Pearson WR, Neal DE, Idle JR. Homozygous deletion of gene for glutathione S-transferase M1 in bladder cancer. Br Med J. 1993;307:481-2.
198. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase Ml (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst. 1993;85:1159-64.
199. Giralt M, Lafuente A, Pujol F, Mallol J. Enhanced glutathione S-transferase activity and glutathione content in human bladder cancer. Followup study: influence of smoking. J Urol. 1993;149: 1452-4.
200. Lafuente A, Pujol F, Carretero P, Villa JP, Cuchi A. Human glutathione S-transferase mu (GST mu) deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. Cancer Lett. 1993;68:49-54.
201. Lin HJ, Han CY, Bernstein DA, Hsiao W, Lin BK, Hardy S. Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis. 1994;15:1077-81.
202. Katoh T, Inatomi H, Nagaoka A, Sugita A. Cytochrome P4501A1 gene polymorphism and homozygous deletion of the glutathione S-transferase M1 gene in urothelial cancer patients. Carcinogenesis. 1995;16:655-7.
203. Kaisary A, Smith P, Jaczq E, McAllister CB, Wilkinson GR, Ray WA, Branch RA. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res. 1987;47:5488-93.
204. Fleming CM, Kaisary A, Wilkinson GR, Smith P, Branch RA. The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer. Pharmacogenetics. 1992;2:128-34.
205. Persad RA, Fleming CM, Wilkinson GR, Smith PJ, Branch RA. Bladder cancer recurrence and its association with cytochrome P-450IID6 activity. Prog Clin Biol Res. 1992;378:19-27.
206. Romkes-Sparks M, Mnuskin A, Chern HD, Persad R, Fleming C, Sibley GN, Smith P, Wilkinson GR, Branch RA. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity. Carcinogenesis. 1994;15:1955-61.
207. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49-53.
208. Scholl P, Musser SM, Kensler TW, Groopman JD. Molecular biomarkers for aflatoxins and their application to human liver cancer. Pharmacogenetics. 1995;5:S171-6.
209. McGlynn KA, Rosvold EA, Lustbader ED, Hu Y, Clapper ML, Zhou T, Wild CP, Xia XL, Baffoe-Bonnie A, Ofori-Adjei D. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci USA. 1995;92:2384-7.
210. Kensler TW, Egner PA, Dolan PM, Groopman JD, Roebuck BD. Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones. Cancer Res. 1987;47:4271-7.
211. Kensler TW, Groopman JD, Eaton DL, Curphey TJ, Roebuck BD. Potent inhibition of aflatoxin-induced hepatic tumorigenesis by the monofunctional enzyme inducer 1,2-dithiole-3-thione. Carcinogenesis. 1992;13:95-100.